Unknown

Dataset Information

Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer.


ABSTRACT: Introduction: Colorectal cancer is one of the most prevalent life-threatening malignant tumors with high incidence and mortality. However, the efficacy of current therapeutic regimens is very limited. Regorafenib has been approved for second- or third-line treatment of patients who are refractory to standard chemotherapy diagnosed with metastatic colorectal cancer, but its clinical efficacy needs to be further improved. Accumulating evidence demonstrates that statins also possess potent anticancer activities. However, whether regorafenib and statins pose synergistic anticancer effects in colorectal cancer is still unclear. Methods: Sulforhodamine B (SRB) assays were applied to evaluate the anti-proliferative activity of regorafenib or/and rosuvastatin in vitro, and imm

SUBMITTER: Yuan T 

PROVIDER: S-EPMC10149949 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature